next-generation Bcr/Abl inhibitors (Deciphera)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namenext-generation Bcr/Abl inhibitors (Deciphera)
Drug Alias NameDP-2494DP-2629
ClassificationSmall molecules
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsAnticancer protein kinase inhibitorsApoptosis stimulants
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDeciphera Pharmaceuticals Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDeciphera Pharmaceuticals Llc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A